Combined statin and niacin therapy remodels the high-density lipoprotein proteome

Circulation

Volumn 118, Issue 12, 2008, Pages 1259-1267

  Green, Pattie S ^a,c   Vaisar, Tomas ^a   Pennathur, Subramaniam ^a,b   Kulstad, J Jacob ^a   Moore, Andrew B ^a   Marcovina, Santica ^a   Brunzell, John ^a   Knopp, Robert H ^a   Zhao, Xue Qiao ^a   Heinecke, Jay W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Division of Gerontology and Geriatric Medicine   (United States)

Author keywords

Arteriosclerosis; Cardiovascular diseases; Drugs; Inflammation; Lipoproteins

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; NICOTINIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEOME;

ADULT; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ACTIVITY; FEMALE; FOURIER TRANSFORM MASS SPECTROMETRY; HUMAN; HUMAN CELL; ION PAIR CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; AGED; AMINO ACID SEQUENCE; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS;

ADULT; AGED; AMINO ACID SEQUENCE; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NIACIN; PROTEOME;

EID: 53449083547     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.770669     Document Type: Article

References (44)

1. Gordon DJ, Rifkind BM. High-density lipoprotein: clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
2. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003;290:2030-2040.
3. Oram JF, Heinecke JW. ATP-binding cassette transporter AI: a cell cholesterol exporter protects against cardiovascular disease. Physiol Rev. 2005;85:1343-1372.
4. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest. 2002;110:899-904.
5. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95: 764-772.
6. Vaisar T, Shao B, Green PS, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans. Curr Atheroscler Rep. 2007; 9:417-424.
7. Davidson WS, Thompson TB. The structure of apolipoprotein A-1 in high density lipoproteins. J Biol Chem. 2007;282:22249-22253.
8. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 1996;263:32-60.
9. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984;259: 12201-12209.
10. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL. Human high density lipoproteins are platforms for assembly of multi-component innate immune complexes. J Biol Chem. 2005;280:32578-32585.
11. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
12. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-764.
13. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res. 2003;44:780-792.
14. Getz GS. Thematic review series: the immune system and atherogenesis: immune function in atherogenesis. J Lipid Res. 2005;46:1-10.
15. Khovidhunkit W, Duchateau PN, Medzihradszky KF, Moser AH, Naya-Vigne J, Shigenaga JK, Kane JP, Grunfeld C, Feingold KR. Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis. 2004;176:37-44.
16. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30:39-49.
17. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during acute phase response. J Clin Invest. 1995;96:2758-2767.
18. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101:13032-13037.
19. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5: 1431-1445.
20. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-756.
21. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics. 2006;6:721-730.
22. Heller M, Schlappritzi E, Stalder D, Nuoffer JM, Haeberli A. Compositional protein analysis of high density lipoproteins in hypercholesterolemia by shotgun LC-MS/MS and probabilistic peptide scoring. Mol Cell Proteomics. 2007;6:1059-1072.
23. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122.
24. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007; 370:153-160.
25. Rader DJ. Illuminating HDL: is it still a viable therapeutic target? N Engl J Med. 2007;357:2180-2183.
26. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
27. Zhao XQ, Phan BA, Chu B, Bray F, Moore AB, Polissar NL, Dodge JT Jr, Lee CD, Hatsukami TS, Yuan C. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am Heart J. 2007;154:239-246.
28. Mendez AJ, Oram JF, Bierman EL. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem. 1991;266:10104-10111.
29. Meng F, Wiener MC, Sachs JR, Burns C, Verma P, Paweletz CP, Mazur MT, Deyanova EG, Yates NA, Hendrickson RC. Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry. J Am Soc Mass Spectrom. 2007;18:226-233.
30. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003;75: 4646-4658.
31. Yates JR 3rd, Morgan SF, Gatlin CL, Griffin PR, Eng JK. Method to compare collision-induced dissociation spectra of peptides: potential for library searching and subtractive analysis. Anal Chem. 1998;70: 3557-3565.
32. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002;74:5383-5392.
33. Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, Apweiler R. The International Protein Index: an integrated database for proteomics experiments. Proteomics. 2004;4:1985-1988.
34. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004;76:4193-4201.
35. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, Resing KA, Ahn NG. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 2005;4:1487-1502.
36. Wiener MC, Sachs JR, Deyanova EG, Yates NA. Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem. 2004;76: 6085-6096.
37. Fu X, Gharib SA, Green PS, Aitken ML, Frazer DA, Park DR, Vaisar T, Heinecke JW. Spectral index for assessment of differential protein expression in shotgun proteomics. J Proteome Res. 2008;7:845-854.
38. Chelius D, Bondarenko PV. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res. 2002;1:317-323.
39. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 2000;49:167-177.
40. Bach-Ngohou K, Ouguerram K, Frenais R, Maugere P, Ripolles-Piquer B, Zair Y, Krempf M, Bard JM. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. J Pharmacol Exp Ther. 2005;315:363-369.
41. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
42. Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M. Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res. 2006;47:1725-1732.
43. Gelissen IC, Hochgrebe T, Wilson MR, Easterbrook-Smith SB, Jessup W, Dean RT, Brown AJ. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J. 1998;331:231-237.
44. Paromov VM, Morton RE. Lipid transfer inhibitor protein defines participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J Biol Chem. 2003;278:40859-40866.